Aquestive Therapeutics
AQST
46 hedge funds and large institutions have $64.4M invested in Aquestive Therapeutics in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 18 reducing their positions, and 19 closing their positions.
32% more call options, than puts
Call options by funds: $1.07M | Put options by funds: $810K
4% more capital invested
Capital invested by funds: $62M → $64.4M (+$2.4M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.7% less ownership
Funds ownership: 42.7% → 38% (-4.7%)
23% less funds holding
Funds holding: 60 → 46 (-14)
33% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 18
74% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$782K |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$580K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$220K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$164K |
| 5 |
JF
Jump Financial
Chicago,
Illinois
|
+$74.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.21M |
| 2 |
CCM
CAAS Capital Management
New York
|
-$862K |
| 3 |
AIMCA
Alberta Investment Management Corp (AIMCo)
Edmonton,
Alberta, Canada
|
-$596K |
| 4 |
Millennium Management
New York
|
-$447K |
| 5 |
E
Ergoteles
New York
|
-$361K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Squarepoint
New York
| – | -$79K | -19,824 | Closed |
|
|
VF
52
Virtu Financial
New York
| – | -$74K | -18,521 | Closed |
|
|
SFI
53
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
| – | -$62K | -15,644 | Closed |
|
|
ECM
54
ExodusPoint Capital Management
New York
| – | -$53K | -13,399 | Closed |
|
55
Jane Street
New York
| – | -$52K | -13,099 | Closed |
|
|
LP
56
LMR Partners
London,
United Kingdom
| – | -$48K | -12,090 | Closed |
|
|
WS
57
Wedbush Securities
Los Angeles,
California
| – | -$42K | -10,500 | Closed |
|
58
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$5.4K | -1,377 | -98% |
|
|
ASN
59
Advisory Services Network
Atlanta,
Georgia
| – | -$3K | -800 | Closed |
|
|
PAM
60
Panagora Asset Management
Boston,
Massachusetts
| – | -$2K | -423 | Closed |
|
61
New York State Common Retirement Fund
Albany,
New York
| – | -$1K | -159 | Closed |
|
|
SAM
62
Strategic Asset Management
Rochester,
Minnesota
| – | +$196 | +50 | New |
|
AQST Hedge Fund Activity: Q3 2021 in Review
46 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q3 2021, worth a combined $64.4M — up 3.9% from $62M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of AQST and 5 opened new positions — a net loss of 14 holders — while 18 trimmed existing stakes and 12 added.
The largest buyer was GSA Capital Partners, adding an estimated $782K. The largest seller was Morgan Stanley, cutting an estimated $1.21M.
- 46 institutional investors held Aquestive Therapeutics (AQST) as of Q3 2021, down from 60 in Q2 2021.
- Funds reported $64.4M of Aquestive Therapeutics stock for Q3 2021, up 3.9% quarter-over-quarter.
- 5 funds opened new Aquestive Therapeutics positions in Q3 2021 and 19 closed out, a net change of -14 holders.
- The largest Aquestive Therapeutics buyer in Q3 2021 was GSA Capital Partners, an estimated $782K added.
- The largest Aquestive Therapeutics seller in Q3 2021 was Morgan Stanley, an estimated $1.21M sold.
Based on aggregated 13F filings for Q3 2021.